Hypoxia-mediated tumour targeting

Gene Therapy

Volumn 10, Issue 7, 2003, Pages 540-549

  Binley, K ^a   Askham, Z ^a   Martin, L ^a   Spearman, H ^a   Day, D ^a   Kingsman, S ^a   Naylor, S ^a  

^a OXFORD BIOMEDICA UK LTD   (United Kingdom)

Author keywords

Expression; GDEPT; Hypoxia; Targeting

Indexed keywords

ADENOVIRUS VECTOR; CYCLOPHOSPHAMIDE; CYTOCHROME P450 2B6; GANCICLOVIR; PRODRUG; THYMIDINE KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DNA RESPONSIVE ELEMENT; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; GENE ACTIVITY; GENE DELIVERY SYSTEM; GENE DIRECTED ENZYME PRODRUG THERAPY; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE TARGETING; GENE THERAPY; HUMAN; HUMAN CELL; HYPOXIA; IN VIVO STUDY; LIVER; LIVER TOXICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; SPLEEN; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALS; ANOXIA; ANTIVIRAL AGENTS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; CYTOMEGALOVIRUS; FEMALE; GANCICLOVIR; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENETIC ENGINEERING; GENETIC VECTORS; HYPOXIA, BRAIN; MELANOMA, EXPERIMENTAL; MICE; MICE, NUDE; POLYMERASE CHAIN REACTION; PRODRUGS; PROMOTER REGIONS (GENETICS); THYMIDINE KINASE; TRANSDUCTION, GENETIC; TUMOR CELLS, CULTURED;

ADENOVIRIDAE; ANIMALIA;

EID: 0037386279     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301944     Document Type: Article

References (41)

1. Shirakawa T et al. Tissue-specific promoters in gene therapy for the treatment of prostate cancer. Mol Urol 2000; 4: 73-82.
2. He P et al. The targeted expression of interleukin-2 in human hepatocellular carcinoma cells. J Exp Clin Cancer Res 2000; 19: 183-187.
3. Vaupel PW. Oxygenation of solid tumours In: Teicher BA (ed). Drug Resistance in Oncology. Marcel Dekker: New York, 1993, pp 53-85.
4. Semenza GL. HIF-1 and human disease: one highly involved factor. Genes Dev 2000; 14: 1983-1991.
5. Maxwell PH, Pugh CW, Ratcliffe PJ. Inducible operation of the erythropoietin 3′ enhancer in multiple cell lines: evidence for a widespread oxygen-sensing mechanism. Proc Natl Acad Sci USA 1993; 90: 2423-2427.
6. Wang GL, Semenza GL. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci USA 1993; 90: 4304-4308.
7. Talks KL et al. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 2000; 157: 411-421.
8. Zhong H et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999; 59: 5830-5835.
9. Semenza GL. Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 1999; 15: 551-578.
10. Aebersold DM et al. Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 2001; 61: 2911-2916.
11. Birner P et al. Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin Cancer Res 2001; 7: 1661-1668.
12. Birner P et al. Expression of hypoxia-inducible factor-1 alpha in oligodendrogliomas: its impact on prognosis and on neoangiogenesis. Cancer 2001; 92: 165-171.
13. Binley K et al. An adenoviral vector regulated by hypoxia for the treatment of ischaemic disease and cancer. Gene Ther 1999; 6: 1721-1727.
14. Boast K et al. Characterisation of physiologically regulated vectors for the treatment of ischemic disease. Human Gene Therapy 1999; 10: 21972208.
15. Griffiths L et al. The macrophage - a novel system to deliver gene therapy to pathological hypoxia. Gene Ther 2000; 7: 255-262.
16. Greco O, Dachs GU. Gene directed enzyme/prodrug therapy of cancer: historical appraisal and future prospectives. J Cell Physiol 2001; 187: 22-36.
17. Brand K et al. Liver-associated toxicity of the HSV-tk/GCV approach and adenoviral vectors. Cancer Gene Ther 1997; 4: 9-16.
18. Franz WM, Rothmann T, Frey N, Katus HA. Analysis of tissue-specific gene delivery by recombinant adenoviruses containing cardiac-specific promoters. Cardiovasc Res 1997, 35: 560-566.
19. Shi Q, Wang Y, Worton R. Modulation of the specificity and activity of a cellular promoter in an adenoviral vector. Hum Gene Ther 1997; 8: 403-410.
20. Bilbao R et al. Transduction efficacy, antitumoral effect, and toxicity of adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir therapy of hepatocellular carcinoma: the woodchuck animal model. Cancer Gene Ther 2000; 7: 657-662.
21. Shinoura N et al. Adenovirus-mediated transfer of bax with caspase-8 controlled by myelin basic protein promoter exerts an enhanced cytotoxic effect in gliomas. Cancer Gene Ther 2000; 7: 739-748.
22. Fechner H et al. Expression of coxsackie adenovirus receptor and alphav-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers. Gene Ther 1999; 6: 1520-1535.
23. Addison CL, Hitt M, Kunsken D, Graham FL. Comparison of the human versus murine cytomegalovirus immediate early gene promoters for transgene expression by adenoviral vectors. J Gen Virol 1997; 78: 1653-1661.
24. Jiang BH, Agani F, Passaniti A, Semenza GL. V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res 1997; 57: 5328-5335.
25. Maxwell PH et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA 1997; 94: 8104-8109.
26. Wiesener MS et al. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas. Cancer Res 2001; 61: 5215-5222.
27. Birner P et al. Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 2000; 60: 4693-4696.
28. Kan O et al. Direct retroviral delivery of human cytochrome P450 2B6 for gene-directed enzyme prodrug therapy of cancer. Cancer Gene Ther 2001; 8: 473-482.
29. Waxman DJ, Chen L, Hecht JE, Jounaidi Y. Cytochrome P450-based cancer gene therapy: recent advances and future prospects. Drug Metab Rev 1999; 31: 503-522.
30. van der Eb MM et al. Severe hepatic dysfunction after adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene and ganciclovir administration. Gene Ther 1998; 5: 451-458.
31. Yamamoto M, Alemany R, Adachi Y, Grizzle WE, Curiel DT. Characterization of the cyclooxygenase-2 promoter in an adenoviral vector and its application for the mitigation of toxicity in suicide gene therapy of gastrointestinal cancers. Mol Ther 2001; 3: 385-394.
32. Brand K et al. Tumor cell-specific transgene expression prevents liver toxicity of the adeno-HSVtk/GCV approach. Gene Ther 1998; 5: 1363-1371.
33. Reynolds PN et al. Combined transductional and transcriptional targeting improves the specificity of transgene expression in vivo. Nat Biotechnol 2001; 19: 838-842.
34. Wickham TJ. Targeting adenovirus. Gene Ther 2000; 7: 110-114.
35. Kruyt FA, Curiel DT. Toward a new generation of conditionally replicating adenoviruses: pairing tumor selectivity with maximal oncolysis. Hum Gene Ther 2002; 13: 485-495.
36. Rodriguez R et al. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res 1997; 57: 2559-2563.
37. Alemany R et al. Complementary adenoviral vectors for oncolysis. Cancer Gene Ther 1999; 6: 21-25.
38. Yamamoto M et al. Characterization of the cyclooxygenase-2 promoter in an adenoviral vector and its application for the mitigation of toxicity in suicide gene therapy of gastrointestinal cancers. Mol Ther 2001; 3: 385-394.
39. Patterson AV et al. Oxygen-sensitive enzyme-prodrug gene therapy for the eradication of radiation-resistant solid tumours. Gene Ther 2002; 9: 946-954.
40. Shibata T, Giaccia AJ, Brown JM. Hypoxia-inducible regulation of a prodrug-activating enzyme for tumor-specific gene therapy. Neoplasia 2002; 4: 40-48.
41. He TC et al. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 1998; 95: 2509-2514.